High-dose IVIG in an early controlled CFS trial
Lloyd A et al. · 1990 · American Journal of Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Three monthly blinded infusions of IVIG at 2 g/kg or placebo. Blinded physicians assessed symptoms and disability three months after the final infusion.
Dose, route and schedule
Three monthly blinded infusions of IVIG at 2 g/kg or placebo. Blinded physicians assessed symptoms and disability three months after the final infusion.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Physician-rated response | 10/23 (43%) with IVIG and 3/26 (12%) with placebo were judged to have improved substantially. |
Small trial in a selected historical cohort. The later 99-person dose-ranging study found no specific benefit.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Small trial in a selected historical cohort. The later 99-person dose-ranging study found no specific benefit.
Source access
Three monthly blinded infusions of IVIG at 2 g/kg or placebo. Blinded physicians assessed symptoms and disability three months after the final infusion.
Source reviewed 2026-11-12.
Citation and original source
Original source: Lloyd A et al.. High-dose IVIG in an early controlled CFS trial American Journal of Medicine 1990.
Molekul research summary: https://molekul.io/research/ivig-lloyd-1990. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry